bioRxivCancer BiologyPreprint
HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex
S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, A. Cherkasov, W. Zwart, C. Collins, T. Bagci-Onder, N. A. Lack
Abstract
HOXB13 is a posterior homeobox protein that is associated with the initiation and growth of prostate cancer (PCa). While most research has focused on the role of HOXB13 on androgen receptor (AR) activity, we demonstrate that HOXB13 is essential to the proliferation of both AR-positive and -negative PCa. Strikingly, HOXB13 is remarkably selective and has almost no effect on non-prostatic tissues. Despite this common essentiality in PCa, HOXB13 activity is markedly different in AR-negative PCa, where interactions with the AP-1 change the HOXB13 cistrome in stem-cell like castration-resistant prostate cancer. We show that HOXB13 activity is commonly mediated by SMARCD2, a member of the mSWI/SNF chromatin remodeling complex. Despite the distinct transcription factor interactions in AR-positive and -negative PCa the HOXB13/SMARCD2 commonly alters chromatin accessibility at HOXB13 binding sites that causes increased proliferation in PCa. Overall, this work demonstrates a novel mechanism of action for HOXB13 and highlights its critical role in AR-negative castration-resistant prostate cancer.
- organism: human
- assay: ChIP-seq
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming
X. Lu, K. W. Fong, … J. Yu·bioRxiv·Oct 4, 2021
- Loss of HOXB13 expression in neuroendocrine prostate cancer
- p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
J. Luo, Z. Chen, … A. M. Chinnaiyan·bioRxiv·Mar 29, 2024
- Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression
J. Uusi-Mäkelä, E. Afyounian, … M. Nykter·bioRxiv·Sep 8, 2020
- MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
N. C. Whitlock, S. Y. Trostel, … A. G. Sowalsky·bioRxiv·Nov 20, 2019
- SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape
I. Grbesa, M. A. Augello, … C. E. Barbieri·bioRxiv·Apr 20, 2021